Preoperative RESpiratory Training and MOBilization to Prevent Postoperative Pulmonary Complications in Patients Undergoing Thoracic Surgery
RESMOB
1 other identifier
interventional
436
1 country
3
Brief Summary
Postoperative pulmonary complications (PPCs) are the most frequent complications occurring in patients undergoing thoracic surgery and they are associated with prolonged hospital stay, decreased survival and expanding medical costs. Implementation of structured and supervised exercise programs including endurance training (ET), respiratory muscle training (RMT) or a combination of both, within the short waiting period before surgery, has been shown to enhance patients' physical fitness, to provide protective effects against PPCs and therefore to spare health care resources by shortening intensive care unit (ICU) and hospital lengths of stay. More recently, a simple intervention consisting in patient's instruction and education about modifiable risk factors, optimal breathing pattern and the impact of physical exercise has emerged as a simple alternative intervention prevent PPCs, although the evidence is inconclusive. Therefore, the investigators propose a multicentre randomized, open, blinded end point controlled trial testing the hypothesis that preoperative education and instruction focused on breathing exercise and endurance training reduce the occurrence of PPCs in patients undergoing thoracic or abdominal surgery. Patients with Intermediate-to-high risks factors for PPCs will be randomized on a 1:1 basis into an intervention arm and a usual care arm (Control group). In the Education group, patients will be asked to use a flow resistive device (One set of 30 repetitions, two times a day and to increase their daily physical activities (\> 5'000 steps or equivalent) until surgery. Primary study endpoint will be the incidence of PPCs (e.g., atelectasis, pneumonia, respiratory failure) according to the European Perioperative Clinical Outcome definitions. Secondary outcomes will include non-respiratory complications, utilization of hospital resources (e.g., hospital length of stay, ICU admission),and preoperative changes in maximal inspiratory pressure \[MIP\]. Assuming a rate of 39% PPCs in the controls and a possible reduction to 26% in the intervention group, enrollment of 203 patients per group will provide 80% power with an alpha value of 0.05. Taking into account dropouts (5%) and in-hospital mortality rate (2%), a total of 436 surgical patients will be enrolled.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jul 2022
Typical duration for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 8, 2022
CompletedFirst Posted
Study publicly available on registry
June 13, 2022
CompletedStudy Start
First participant enrolled
July 20, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 10, 2024
CompletedDecember 27, 2023
December 1, 2023
2 years
June 8, 2022
December 23, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The incidence of postoperative pulmonary complications
Postoperative pulmonary complications will be investigated during the postoperative 5 days. These complications are named according to the European Perioperative Clinical Outcome (EPCO) definitions (Respiratory failure, aspiration pneumonitis, pneumonia, ARDS, pneumothorax, atelectasis, bronchospasm)
Up to postoperative 5 days
Secondary Outcomes (5)
Preoperative MIP change
7 days
Length of stay in hospital
Up to 15 days
Visual Analog Scale thoracic rest pain
Up to 5 days
Visual Analog Scale thoracic coughing pain
Up to 5 days
Visual Analog Scale dyspnea
Up to 5 days
Study Arms (2)
Usual Care
NO INTERVENTIONPatients who are candidates for thoracic resection surgeries will be advised to stay active and quit smoking.
Intervention group
ACTIVE COMPARATORPatients who are candidates for thoracic resection surgeries will be handed a flow resistive device that helps inspiratory muscle training (2\*30 repetitions a day for 7 days) and will be advised to walk 5000 steps a day.
Interventions
Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
Eligibility Criteria
You may qualify if:
- Adult patients (\> 18 years)
- Risk factors for PPCs (ARISCAT score \>27)
- Elective intra-abdominal surgery or intrathoracic surgery via an open or minimally-invasive approach, expected to last \> 120 min.
You may not qualify if:
- Patients unable to understand the instructions and/or to perform the proposed training program (i.e., poor comprehension, chest pain)
- COPD GOLD Grade III and IV, lung fibrosis, documented bullae, severe emphysema, pneumothorax
- Patient with chest pain or at risk of pneumothorax
- Previous lung surgery
- Bilateral lung procedures
- Emergent surgery or organ transplant
- Planned mechanical ventilation after surgery
- Uncontrolled asthma
- Coronary heart disease with angina grade 3 or 4 Canadian Cardiovascular Society
- documented pulmonary arterial hypertension \>25mmHg mean pulmonary arterial pressure (PAP) at rest or \> 40 mmHg systolic PAP (estimated by ultrasound)
- Documented or suspected neuromuscular disease (thymoma, myasthenia, myopathies, muscular dystrophies, others)
- Intracranial injury or tumor
- Persistent hemodynamnic instability, intractable shock
- Pregnancy (excluded by anamnesis and/or laboratory analysis)
- Enrollment in another interventional study or refusal of informed consent
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Acıbadem Mehmet Ali Aydınlar University, Faculty of Medicine
Istanbul, Turkey (Türkiye)
Istanbul University Istanbul Faculty of Medicine
Istanbul, Turkey (Türkiye)
Koc University, Faculty of Medicine
Istanbul, Turkey (Türkiye)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Emre S Bingul, MD
Istanbul University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- CARE PROVIDER, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Doctor, Lecturer
Study Record Dates
First Submitted
June 8, 2022
First Posted
June 13, 2022
Study Start
July 20, 2022
Primary Completion
July 10, 2024
Study Completion
July 10, 2024
Last Updated
December 27, 2023
Record last verified: 2023-12